tbuckley/cabot-search huggingface dataset:
P155 Non-invasive ventilation (NIV) in acute hypercapnic respiratory failure in restrictive lung diseases (RLD)
Authors: A. Thomas, A. Ali, B. Chakraborty, B. Beauchamp, E. Gallagher, D. Banerjee, R. Mukherjee
Journal: Thorax (2010)

<h3>Introduction</h3> Successful NIV has been described in RLD (thoracic cage disease, obesity-hypoventilation and neuromuscular diseases) and given the success in chronic ventilatory failure, NIV should be considered as the treatment of choice in decompensated ventilatory failure due to RLD in an acute setting. <h3>Methods</h3> Analysis of initial ABG in those admitted to a NIV unit on a respiratory ward with a diagnosis of RLD, requiring NIV for an acute episode of respiratory failure (pH &lt;7.35 and pCO<sub>2</sub> &gt;6.0 kPa) admitted between 01 August 2004 and 31 December 2009. Patients included were those with respiratory failure as a consequence of RLD. Those who were either admitted or managed in HDU were excluded from the analysis. The admission episodes were stratified by initial pH ranges (predictor variable) and in-hospital mortality was recorded (outcome variable). <h3>Results</h3> In 270 admissions (221 unique patients) with RLD requiring NIV for acute respiratory failure, the overall mortality was 35 (13.0%). There was a significant increase in mortality in the group where ABG pH&lt;7.15 (40.9%). The difference is significant when compared to the group with a pH between 7.15 and 7.26 (9.6%) (p=0.027). There was no significant difference in mortality in the group with pH 7.15 to 7.26 to the group with pH 7.26 to 7.35 (p=0.94): See Abstract P155 Figure 1. The plot of fitted logistic regression equation with initial pH (the dotted lines indicate 95% confidence band). <h3>Conclusion</h3> For those patients with RLD treated with NIV on a respiratory ward, the mortality increases with the severity of acidosis. As no current guidelines indicate a pH cut-off for the ward based management of RLD with NIV, from our results we propose that this could be an initial ABG pH of 7.15.
P17 * MANAGEMENT AND OUTCOMES OF MIDLINE LOW-GRADE GLIOMAS
Authors: M. Waqar, S. Hanif, N. Rathi, K. Das, R. Zakaria, A. R. Brodbelt, C. Walker, M. Jenkinson
Journal: Neuro-Oncology (2014)

INTRODUCTION: Low-grade gliomas (LGGs) are slow-growing and diffusely infiltrating tumours constituting 25-30% of adult gliomas. Rarely, these tumours may arise in the cerebral midline, including the thalamus, hypothalamus, tectum and brainstem. Here we present a contemporary experience with midline LGGs. METHOD: Midline LGGs were identified from a retrospective database of adult patients who received a histological diagnosis of WHO grade II glioma between 2006-2012 at a single institution. Location, radiological data and clinical outcomes were collected. IDH1 status was assessed by immunohistochemistry. RESULTS: 18 patients with midline LGGs were identified, with a median age of 45. Most received biopsy upon diagnosis, though asymptomatic patients with tectal tumours underwent active surveillance. Oligodendroglial tumours were much less common than in a comparable group of lobar tumours (6% vs 38%, Fisher's Exact Test, p = 0.007). Only one tumour was immunopositive for IDH1 (6%). Radiological diagnosis correlated with histology in only 71% of patients. Median survival of midline LGGs was 48 months (3-90 months) and radiological features such as contrast enhancement, size and radiological diagnosis did not predict survival in this cohort. Median overall survival of midline LGGs was less than lobar LGGs (Log-rank, p = 0.006), though differences became insignificant when considering only biopsied astrocytomas in both locations (Log-rank, p = 0.491). CONCLUSION: Diagnosis of midline LGGs is complicated by both limitations of biopsy and imaging. Midline tumours have a poorer prognosis compared to lobar equivalents and survival differences are probably due to the absence of significant surgical intervention in midline locations.
REFRACTORY CARDIOGENIC SHOCK TREATED BY VENO-ARTERIAL ECMO; PROGNOSTIC ROLE OF LACTATE
Authors: Ervis Hiso, Daniele Scarpa, Martina Perazzolo Marra, Luciano Babuin, Giuseppe Tarantini, Gino Gerosa, Sabino Iliceto, Luisa Cacciavillani
Journal: Journal of the American College of Cardiology (2016)
Abstract P3-01-05: The Role of Mammographic Calcification in the Neo-adjuvant Therapy of Breast Cancer Imaging Evaluation
Authors: JJ Li, CM Chen, GH Di, J Wu, JS Lu, Z-M Shao
Journal: Cancer Research (2012)

Abstract Aim: To evaluate the relationship between malignant appearance of mammographic calcification and breast cancer pathological features, and to explore the predictive value of calcification appearances and morphology changes in neo-adjuvant setting. Methods: 419 patients with operable breast cancer received neo-adjuvant therapy between 2008.2 and 2011.8 in Shanghai Cancer Hospital. Core needle biopsy was conducted before preoperative therapy to determine cancer and achieve pathological features. Mammogram (MG), ultrasound and breast MRI were routinely done prior to therapy and prior to surgical operation. We conducted a detailed analysis of MG images in patients with malignant calcification, recorded the morphology, distribution, range, density, diameter and number of the calcification. Results: 419 patients enrolled, 108 patients (25.8%) showed malignant calcification in MG, 6 patients missed the first MG before therapy. 214 patients were Luminal A, 95 were Luminal B, 64 were Her2 positive and 46 were triple negative, the pCR rate was 14%, 30.5%, 53%, 43.5% respectively. Patients with malignant calcification have more ER positive (81.5% vs. 71.7%, p = 0.045) and HER2 positive (51.8% vs. 33%, p = 0.001) diseases. The pCR rate was 26% in patients with malignant calcification and 28% in patients without, p = 0.8. Different morphology shapes showed similar pCR rate, p = 0.89. Casting-type had a higher pCR rate 45.8%, compared with 20% in crushed stone-like and 16.7% in powderish, p = 0.031. Range more than 5cm had a higher pCR rate, 40.7% vs. 20%, p = 0.034. Density, diameter and number of the calcification did not reach statistical difference, however high density, diameter &amp;gt;1mm and number &amp;gt;20 per cm2 showed a trend of higher pCR rate. Patients with diameter ≤0.5mm had a higher lymphatic vascular invasive rate 51.4%, compared to diameter≤1mm (26.8%) and diameter &amp;gt;1mm (22.7%), p = 0.03. Morphology and distribution of calcification did not change obviously. Less than 30% patients showed changes in range, number or density, no relationship with pCR rate. Conclusion: Patients with malignant calcification are more likely to have ER positive and Her2 positive diseases. MG should be considered the standard prior to the start of therapy, the distribution and range of the calcification may predict pCR rate. Calcification appearance does not change significantly after neo-adjuvant therapy, therefore MG is not an appropriate method for efficacy evaluation. But MG before surgery is still useful to identify the extent of surgery, especially in breast conserve therapy. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-01-05.
Abstract 4976: Characterization of the neuroinflammatory response in a mouse model of brain metastatic inflammatory breast cancer.
Authors: L. Tiffany Reed, Diane Palmieri, Ginny Mason, Patricia Steeg
Journal: Cancer Research (2013)

Abstract Inflammatory Breast Cancer (IBC) is a rare form of breast cancer, accounting for approximately 2% of all breast cancer cases worldwide. While rare, it is extremely progressive and has a high propensity for metastatic spread and decreased overall survival compared to non-IBC breast cancers. IBC has a five-year overall survival rate of 30%; the median age at diagnosis is 57 years of age. Approximately 15% of IBC patients develop brain metastasis, and most of the brain metastasizing IBC tumors are triple negative (ER-, PR- and HER2-) or Her-2 overexpressing. The goal of this study was to investigate the neuroinflammatory response of SUM190 cells, a Her-2 overexpressing IBC cell line, in a mouse model of brain metastasis. The SUM190 brain metastatic mouse model of IBC was developed following three-sequential rounds of injection of cells into the left cardiac ventricle, isolation of metastatic tumor cells from the brains of the mice, and growth in tissue culture to maintain brain metastatic potential of the cell line. In this model, brain metastases were widely disseminated throughout the neuroparenchyma. The lesions were round, and measured 0.5-1 mm in maximal diameter, with a central area of necrosis characterized by shrunken hypereosinophilic epithelial cells with karryorhectic or absent nuclei. There was no significant difference in vascular proliferation in the peritumoral microenvironment compared to the unaffected neuroparenchyma (p=0.57) following quantitative immunofluorescent analysis. However, there was a 4-fold increase in GFAP-positive astrocytes (p=&amp;lt;0.0001) and CD11b-positive microglia (p=0.001) and a 3-fold increase in F4/80-positive macrophages (p=0.001) in the tumor microenvironment compared to the unaffected neuroparenchyma. CD3+ T cells were widely disseminated throughout the tumor microenvironment. The influx of inflammatory cells in brain metastases associated with IBC is greater than that of other brain-tropic breast cancer cell lines including MDA-MB-231-BR, and may explain the increased incidence of metastasis in IBC patients. This research was supported by the NIH Intramural Research Program and a grant from the Inflammatory Breast Cancer Research Foundation. Citation Format: L. Tiffany Reed, Diane Palmieri, Ginny Mason, Patricia Steeg. Characterization of the neuroinflammatory response in a mouse model of brain metastatic inflammatory breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4976. doi:10.1158/1538-7445.AM2013-4976
FE-HBED AND FE-EHPG: IRON COMPLEXES EXHIBITING HEPATOBILIARY ENHANCEMENT IN MRI.
Authors: Barry L. Engelstad, Emiliano C. Ramos, Homer A. Macapinlac, Thomas R. Johnson, David L. White, Michael E. Moseley
Journal: Clinical Nuclear Medicine (1986)

Engelstad, Barry L.; Ramos, Emiliano C.; Macapinlac, Homer A.; Johnson, Thomas R.; White, David L.; Moseley, Michael E. Author Information
Phase I Study on the Sequential Administration of Recombinant Human Interferon- and Recombinant Human Interleukin-2 in Patients With Metastatic Solid Tumors
Authors: J. W. Baars, J. Wagstaff, E. Boven, J. B. Vermorken, C. J. van Groeningen, R. J. Scheper, J. C. M. Fonk, H. W. Nijman, C. R. Franks, O. Damsma, H. M. Pinedo
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Phase I Study on the Sequential Administration of Recombinant Human Interferon-γ and Recombinant Human Interleukin-2 in Patients With Metastatic Solid Tumors Get access Johanna W. Baars, Johanna W. Baars Department of Medical Oncology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar John Wagstaff, John Wagstaff * Department of Medical Oncology, Free University HospitalAmsterdam, The Netherlands * Correspondence to: John Wagstaff, M.D., M.R.C.P., Department of Medical Oncology, Free University Hospital, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Epie Boven, Epie Boven Department of Medical Oncology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Jan B. Vermorken, Jan B. Vermorken Department of Medical Oncology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Cees J. van Groeningen, Cees J. van Groeningen Department of Medical Oncology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Riekeld J. Scheper, Riekeld J. Scheper Department of Pathology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Johanna C. M. Fonk, Johanna C. M. Fonk Department of Pathology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Hans W. Nijman, Hans W. Nijman Department of Medical Oncology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Christopher R. Franks, Christopher R. Franks EuroCetus BV, Amsterdam Search for other works by this author on: Oxford Academic PubMed Google Scholar Otto Damsma, Otto Damsma Boehringer Ingelheim BVAlkmaar, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar ... Show more Herbert M. Pinedo Herbert M. Pinedo Department of Medical Oncology, Free University HospitalAmsterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 19, 2 October 1991, Pages 1408–1410, https://doi.org/10.1093/jnci/83.19.1408 Published: 02 October 1991 Article history Received: 27 March 1991 Revision received: 02 July 1991 Accepted: 08 July 1991 Published: 02 October 1991
Case 22-2012
Authors: Wendy Macías Konstantopoulos, Michele Burns Ewald, Daniel S. Pratt
Journal: New England Journal of Medicine (2012)

A 34-year-old man was seen in the emergency department because of abdominal pain and vomiting after his wife had given him a powder to cause him to stop drinking alcohol. The substance was identified, diagnostic tests were performed, and management decisions were made.
Abstract LB-337: Post-transcriptional regulators of microRNA biogenesis drive glioblastoma-specific expression
Authors: Wei-Jen Chung, Pavel Sumazin, Xuerui Yang, Mukesh Bansal, Andrea Califano
Journal: Cancer Research (2011)

Abstract MicroRNAs have emerged as key regulators of both normal and pathologic phenotypes, including cancer. Fine grain regulation of their biogenesis, however, is still a poorly understood process and only a relatively small repertoire of proteins controlling its key steps has been characterized. In order to understand the extent and specificity of microRNA biogenesis control, as well as its role in glioblastoma tumorigenesis and progression, we developed and experimentally validated miRage, an algorithm for genome-wide inference of microRNA biogenesis regulators. MiRage identifies biogenesis-regulator candidates using the conditional mutual information between the candidates, mature microRNAs precursors, and abundance to identify those proteins that are required for the maturation of microRNAs. miRage predicted hundreds of potential biogenesis regulators that are either specific to individual microRNAs or to microRNA families. Several of the inferred regulators that are differentially expressed across glioblastoma prognosis were validated in the SNB19 cell line. Differential expression of mature microRNAs, their host genes, and their precursors were measured before and after ectopic expression or RNAi mediated silencing of predicted regulators. ACSM3, which is predicted to regulate 70% of the differentially expressed microRNAs in glioblastoma, was shown to post-transcriptionally inhibit miR-155. This microRNA is an experimentally validated regulator of CEBPβ, a master regulator of the mesenchymal signature of GBM; indeed siRNA-mediated silencing of ACSM3 dramatically activated miR-155 and down-regulated CEBPβ. In addition, several members of the DDX RNA-binding protein family were inferred as specific regulators of microRNA biogenesis. For instance, we show that DDX10 activates miR-218 and inhibits miR-9; up regulation of DDX10 may account for miR-218 overexpression in poor-prognosis tumors. We showed that RBBP4 inhibits miR-23b, WDR8 inhibits miR-18b, ACTA2 inhibits miR-218, and PRIC285 inhibits miR-196a and miR-25. Taken together, these results suggest that microRNA biogenesis is a much more complex and finely regulated process than previously thought, and that microRNA biogenesis regulators may play a key role in tumor initiation and progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-337. doi:10.1158/1538-7445.AM2011-LB-337
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study
Authors: François Bertucci, Mahmoud Fekih, Aurélie Autret, Thierry Petit, Florence Dalenc, Christelle Levy, Gilles Romieu, Jacques Bonneterre, Jean-Marc Ferrero, Pierre Kerbrat, Patrick Soulie, Marie-Ange Mouret-Reynier, Thomas Bachelot, Florence Lerebours, Jean-Christophe Eymard, Mathilde Deblock, Alain Lortholary, Anne-Claire Hardy-Bessard, Philippe Barthelemy, Hervé Bonnefoi, Emmanuelle Charafe-Jauffret, François-Clément Bidard, Patrice Viens, Jérôme Lemonnier, Jean-Yves Pierga
Journal: The Lancet Oncology (2016)
COMPARE MAJOR BLEEDING RISK AND ASSOCIATED COSTS AMONG NVAF PATIENTS WITH CHA2DS2-VASC SCORE ≥ 3 NEWLY ANTICOAGULATED WITH APIXABAN VERSUS WARFARIN
Authors: Steven Deitelzweig, Kiran Gupta, Augustina Ogbonnaya, Manan Shah, Eileen Farrelly, Tasneem Lokhandwala, Michael Eaddy
Journal: Journal of the American College of Cardiology (2016)
Reproductive Failure in Males with Cystic Fibrosis
Authors: Elvin Kaplan, Harry Shwachman, Alan D. Perlmutter, Allyn Rule, Kon-Taik Khaw, Douglas S. Holsclaw
Journal: New England Journal of Medicine (1968)

Adult males with cystic fibrosis are infertile because of failure of normal development of the vas deferens, a finding not previously recognized. Twenty-five patients over 17 years of age were found to have aspermia. Semen volume was reduced and was more acidic than that of controls. Fructose concentration was diminished. Citric acid and acid phosphatase were increased. Surgical and autopsy specimens showed an absent vas deferens. The testes appeared normal or diminished in size. The epididymides were markedly reduced or partially absent. Histologic examination of all postpubertal testes revealed decreased spermatogenesis with frequent abnormal sperm forms. Clinical examination confirmed the surgical and autopsy findings. Among 15 males with cystic fibrosis married for 46 years, only one offspring is reported. In contrast, 18 married women with cystic fibrosis have had nine children.
Changing hepatitis A epidemiology in the European Union: new challenges and opportunities
Authors: C M Gossner, E Severi, N Danielsson, Y Hutin, D Coulombier
Journal: Eurosurveillance (2015)

This perspective on hepatitis A in the European Union and European Economic Area (EU/EEA) presents epidemiological data on new cases and outbreaks and vaccination policies. Hepatitis A endemicity in the EU/EEA ranges from very low to intermediate with a decline in notification rates in recent decades. Vaccination uptake has been insufficient to compensate for the increasing number of susceptible individuals. Large outbreaks occur. Travel increases the probability of introducing the virus into susceptible populations and secondary transmission. Travel medicine services and healthcare providers should be more effective in educating travellers and travel agents regarding the risk of travel-associated hepatitis A. The European Centre for Disease Prevention and Control (ECDC) endorses the World Health Organization's recommendations on vaccination of high-risk groups in countries with low and very low endemicity and on universal vaccination in countries with intermediate endemicity. Those recommendations do not cover the use of hepatitis A vaccine to control outbreaks. ECDC together with EU/EEA countries should produce evidence-based recommendations on hepatitis A immunisation to control outbreaks. Data about risk behaviours, exposure and mortality are scarce at the EU/EEA level. EU/EEA countries should report to ECDC comprehensive epidemiological and microbiological data to identify opportunities for prevention.
The Neuropathic Postural Tachycardia Syndrome
Authors: Giris Jacob, Fernando Costa, John R. Shannon, Rose Marie Robertson, Mark Wathen, Michael Stein, Italo Biaggioni, Andy Ertl, Bonnie Black, David Robertson
Journal: New England Journal of Medicine (2000)

The postural tachycardia syndrome is a common disorder that is characterized by chronic orthostatic symptoms and a dramatic increase in heart rate on standing, but that does not involve orthostatic hypotension. Several lines of evidence indicate that this disorder may result from sympathetic denervation of the legs.
Abstract 722: Significance of p16 in site-specific HPV-positive and HPV-negative HNSCC
Authors: Josena K. Stephen, George Divine, Kangmei Chen, Dhananajay Chitale, Shaleta Havard, Maria J. Worsham
Journal: Cancer Research (2012)

Abstract Expression of p16INK4A (p16+ve) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinoma (HNSCC), however, p16-positivityis not limited to HPV-positive (HPV+ve) tumors and therefore, not a perfect surrogate for HPV. Also, p16+ve status has a strong relationship with survival and treatment outcomes in HNSCC, which is best documented for the oropharyngeal site (OP); non-OP sites such as the oral cavity (OC), larynx, and hypopharynx (HP) are understudied. The goal of this study was to evaluate p16 in the context of HPV and examine p16 survival outcomes in HPV+ve and HPV-negative (HPV-ve) site-specific HNSCC. The cohort of 80 primary HNSCC consisted of 10 HPV16+ve and 10 HPV16-ve cases each for four sites: OC, OP, larynx and HP. Expression of p16 was significantly different across sites (p&amp;lt;0.001), being more frequent in OP (65%) than in non-OP sites (13%). The frequency of p16 expression was different (p=0.031) between Caucasian Americans (CA, 38%) and African Americans (AA, 16%) similar to HPV (CA 65% vs AA 37%, p=0.013). p16+ve patients had improved survival for all sites combined and for the OP subgroup (similar to HPV+ve cases). However, subgroups defined by both HPV and p16, indicate that patients with p16-negative (-ve)/HPV-ve status had the worst survival for all sites combined as well as for OP. Cohorts with larger representations of non-OP sites examining multiple molecular markers will be key to deciphering and dissecting out p16's role as a useful prognostic indicator when assessed in combination with HPV status Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 722. doi:1538-7445.AM2012-722
Familial Nonhemolytic Jaundice with Normal Liver Histology and Conjugated Bilirubin
Authors: Bernard J. Haverback, Samuel K. Wirtschafter
Journal: New England Journal of Medicine (1960)

RECENTLY there has been considerable interest concerning two syndromes of familial nonhemolytic jaundice. The first syndrome has had various designations: Gilbert's disease1; familial nonhemolytic jaundice2; constitutional hyperbilirubinemia3; and constitutional hepatic dysfunction.4 This disease is characterized clinically by the presence of jaundice, which is either fluctuating or persistent. The patient remains in good health. The serum bilirubin levels are usually less than 6 mg. per 100 ml. and react with the van den Bergh reagent to give predominantly the indirect reaction. A variant of this syndrome was described by Crigler and Najjar5 as occurring in infants in whom . . .